IRIDEX Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY Revenue (est.)
$53Mnext fiscal year
FY EPS (est.)
-$0.05next fiscal year
Monitoring Framework
Key Performance Indicators
Cyclo G6 Probes Sold Quarterly15.5K
Cyclo G6 Glaucoma Laser Systems Sold Quarterly24.0
Total Revenue Quarterly11.8M
Gross Margin Quarterly40.0%Target: 45-50%
Watch Items
- Gross Margin Pressure from Manufacturing Transition and TariffsTrigger: Gross margin falling below 38%Action: Accelerate transition to lower-cost contract manufacturers and optimize pricing strategies.
- International Supply Constraints and Delayed Regulatory ApprovalsTrigger: Retina product revenue declining more than 15% YoYAction: Engage local regulatory consultants and diversify international distribution channels.
Research as of 20 Jun 2026